Moxilubant maleate

Drug Profile

Moxilubant maleate

Alternative Names: CGS 25019C

Latest Information Update: 26 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics
  • Mechanism of Action Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 30 Nov 1998 CGS 25019C is now called Moxilubant maleate
  • 30 Nov 1998 Investigation in Psoriasis in USA (PO)
  • 30 Nov 1998 No-Development-Reported for Rheumatoid arthritis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top